Sandoz receives approval in Europe for Rixathon to treat blood cancers and immunological diseases

Today's approval of Rixathon represents a big win for patients in Europe with blood cancers or immunological diseases because it enables increased access to biologics. It also allows healthcare systems to redeploy resources to other areas of high need, particularly innovative therapies said Carol Lynch, Global Head, Biopharmaceuticals, Sandoz. Sandoz is committed to increasing patient access to biologic medicines, and Rixathon will be one of the five major launches we plan in the next four years. We have worked with care and passion towards this approval, and now is the time when we are bringing this medicine to healthcare professional and patients in Europe.

Spotlight

Spotlight

Related News